Anifrolumab: First Biologic Approved in the EU Not Restricted to Patients with a High Degree of Disease Activity for the Treatment of Moderate to Severe Systemic Lupus Erythematosus.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY（2024）
Key words
Anifrolumab,biologics,COVID-19,cutaneous lupus erythematosus,herpes zoster,systemic lupus erythematosus,type I interferons
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined